Paolo Tombesi - Aug 17, 2022 Form 4 Insider Report for Turning Point Therapeutics, Inc. (TPTX)

Role: EVP & Chief Financial Officer
Signature: /s/ Paolo Tombesi
Stock symbol: TPTX
Transactions as of: Aug 17, 2022
Transactions value $: -$2,263,128
Form type: 4
Date filed: 8/17/2022, 04:31 PM
Previous filing: Jul 29, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TPTX	Common Stock	Disposed to Issuer	-$2.26M	-29.8K	-100%	$76.00	0	Aug 17, 2022	Direct	F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TPTX	Stock Option (right to buy)	Disposed to Issuer		-61.2K	-100%		0	Aug 17, 2022	Common Stock	61.2K	$62.63	Direct	F4
transaction	TPTX	Stock Option (right to buy)	Disposed to Issuer		-58.6K	-100%		0	Aug 17, 2022	Common Stock	58.6K	$37.68	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Paolo Tombesi is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 2, 2022, by and among Turning Point Therapeutics, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and Rhumba Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on August 17, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for $76.00 per Share in cash, without interest, subject to any applicable withholding of taxes (the "Cash Amount"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Cash Amount.
F2	At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding restricted stock unit award ("RSU") whether vested or unvested was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to $76.00 per Share issuable in settlement of such RSU immediately before the effective time of the Merger, net of any withholding taxes required to be deducted and withheld by applicable law.
F3	Includes 1,078 shares acquired on June 10, 2022 pursuant to the Issuer's Employee Stock Purchase Plan.
F4	At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law.